OBGYN & Reproduction Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN & Reproduction Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Obesity Therapy
Pramlintide promotes satiety in obese subjects and those with type 2 diabetes
July 4th, 2005
Pramlintide promotes satiety in obese subjects and those with type 2 diabetes. According to a study from the United States, "Long-term trials in insulin-treated subjects with type 2 diabetes have shown that adjunctive treatment with the amylin analogue pramlintide reduces HbA(1)c levels and elicits weight loss. While amylin reduces food intake in rodents, pramlintide's effect on satiety and food intake in humans has not yet been assessed." I. Chapman and colleagues, Amylin Pharmaceutical explained, "In this randomized, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60±9 years, BMI...
Source: OBGYN & Reproduction Week (2005-07-04)
|
